ArticleFrontiers in oncology2026
Clinicopathological and molecular features of gynecologic perivascular epithelioid cell tumors: a single-center study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiologically atypical lymphangioleiomyomatosis presenting with chylous pulmonary congestion, recurrent chylothorax and extrapulmonary cystic lymphatic lesions: A case report.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Perivascular epithelioid cell tumors (PEComas) are rare neoplasms characterized by the expression of both melanocytic and myoid markers. Gynecologic PEComa may show overlapping with smooth muscle tumors and other uterine tumors. The rarity and ill-defined risk stratification make the diagnosis challenging. The current study was aimed to more fully characterize gynecologic PEComas. Methods: We investigated the clinicopathological and immunohistochemical features of nine gynecological PEComas from a single center. The molecular landscape was assessed using a combined DNA-RNA hybrid capture-based comprehensive genomic profiling assay. Results: Patients, aged from 27 to 79 years old, presented with the disease predominantly located in the uteri (5/9) and cervix (3/9). Histologically, six cases were classified as malignant and three as having uncertain malignant potential. All tumors were composed of epithelioid or spindled cells arranged around the vessels, with variable nuclear atypia and necrosis. Immunohistochemical analysis revealed universal HMB45 and TFE3 positivity, and variable myoid marker expression. HMB45 was confirmed as the most sensitive diagnostic marker. Mutually exclusive genetic alterations were identified in all six tested cases with TSC2 mutations/deletions in three tumors and TFE3 fusions in another three. And here we reported a novel YAP1-TFE3 gene fusion in gynecological site. It was found TSC2-altered tumors harbored more additional mutations, whereas TFE3-rearranged tumors occurred in younger patients. Most cases showed malignant potential or malignancy, necessitating risk stratification according to the current WHO algorithms. Conclusions: This study highlights the key histological and molecular features, and advocates for integrated DNA/RNA sequencing to guide prognosis and targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.